Taking into account the fact that MAP kinases, including Erk1/2, can be implicated in HNSCC cell insensitivity to anti-tumor therapeutic approaches, we aimed to determine whether HNSCC cells with activated Erk1/2 are vulnerable to ferroptosis induction and whether ferroptosis development can be modulated by the inhibition of Erk1/2 expression and phosphorylation. This evidence concerns the gene MAPK3 and neoplasm.